169 related articles for article (PubMed ID: 1436716)
1. The long-acting cholinesterase inhibitor heptyl-physostigmine attenuates the scopolamine-induced learning impairment of rats in a 14-unit T-maze.
Iijima S; Greig NH; Garofalo P; Spangler EL; Heller B; Brossi A; Ingram DK
Neurosci Lett; 1992 Sep; 144(1-2):79-83. PubMed ID: 1436716
[TBL] [Abstract][Full Text] [Related]
2. Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze.
Iijima S; Greig NH; Garofalo P; Spangler EL; Heller B; Brossi A; Ingram DK
Psychopharmacology (Berl); 1993; 112(4):415-20. PubMed ID: 7871051
[TBL] [Abstract][Full Text] [Related]
3. The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat.
De Sarno P; Pomponi M; Giacobini E; Tang XC; Williams E
Neurochem Res; 1989 Oct; 14(10):971-7. PubMed ID: 2608162
[TBL] [Abstract][Full Text] [Related]
4. Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates.
Rupniak NM; Tye SJ; Brazell C; Heald A; Iversen SD; Pagella PG
J Neurol Sci; 1992 Feb; 107(2):246-9. PubMed ID: 1564524
[TBL] [Abstract][Full Text] [Related]
5. The behavioral effects of heptyl physostigmine, a new cholinesterase inhibitor, in tests of long-term and working memory in rodents.
Dawson GR; Bentley G; Draper F; Rycroft W; Iversen SD; Pagella PG
Pharmacol Biochem Behav; 1991 Aug; 39(4):865-71. PubMed ID: 1763105
[TBL] [Abstract][Full Text] [Related]
6. Side effects of physostigmine as a pretreatment in guinea pigs.
Philippens IH; Wolthuis OL; Busker RW; Langenberg JP; Melchers BP
Pharmacol Biochem Behav; 1996 Sep; 55(1):99-105. PubMed ID: 8870044
[TBL] [Abstract][Full Text] [Related]
7. Acetylcholinesterase inhibition and anti-soman efficacy of homologs of physostigmine.
Harris LW; Anderson DR; Pastelak AM; Bowersox SL; Vanderpool BA; Lennox WJ
Drug Chem Toxicol; 1992; 15(2):127-43. PubMed ID: 1597127
[TBL] [Abstract][Full Text] [Related]
8. Acetylcholinesterase inhibition by (+)physostigmine and efficacy against lethality induced by soman.
Harris LW; Anderson DR; Pastelak AM; Vanderpool B
Drug Chem Toxicol; 1990; 13(2-3):241-8. PubMed ID: 2276342
[TBL] [Abstract][Full Text] [Related]
9. An inverted U-shaped curve for heptylphysostigmine on radial maze performance in rats: comparison with other cholinesterase inhibitors.
Braida D; Paladini E; Griffini P; Lamperti M; Maggi A; Sala M
Eur J Pharmacol; 1996 Apr; 302(1-3):13-20. PubMed ID: 8790986
[TBL] [Abstract][Full Text] [Related]
10. Heptyl-physostigmine enhances basal forebrain control of cortical cerebral blood flow.
Linville DG; Giacobini E; Arnerić SP
J Neurosci Res; 1992 Mar; 31(3):573-7. PubMed ID: 1640506
[TBL] [Abstract][Full Text] [Related]
11. Maze learning in aged rats is enhanced by phenserine, a novel anticholinesterase.
Ikari H; Spangler EL; Greig NH; Pei XF; Brossi A; Speer D; Patel N; Ingram DK
Neuroreport; 1995 Feb; 6(3):481-4. PubMed ID: 7766848
[TBL] [Abstract][Full Text] [Related]
12. Subchronic physostigmine pretreatment in guinea pigs: effective against soman and without side effects.
Philippens IH; Busker RW; Wolthuis OL; Olivier B; Bruijnzeel PL; Melchers BP
Pharmacol Biochem Behav; 1998 Apr; 59(4):1061-7. PubMed ID: 9586868
[TBL] [Abstract][Full Text] [Related]
13. Preclinical investigation of the topical administration of phenserine: transdermal flux, cholinesterase inhibition, and cognitive efficacy.
Utsuki T; Uchimura N; Irikura M; Moriuchi H; Holloway HW; Yu QS; Spangler EL; Mamczarz J; Ingram DK; Irie T; Greig NH
J Pharmacol Exp Ther; 2007 Apr; 321(1):353-61. PubMed ID: 17255466
[TBL] [Abstract][Full Text] [Related]
14. The cholinesterase inhibitor, phenserine, improves Morris water maze performance of scopolamine-treated rats.
Janas AM; Cunningham SC; Duffy KB; Devan BD; Greig NH; Holloway HW; Yu QS; Markowska AL; Ingram DK; Spangler EL
Life Sci; 2005 Jan; 76(10):1073-81. PubMed ID: 15620572
[TBL] [Abstract][Full Text] [Related]
15. Physostigmine-induced hypothermic response in rats and its relationship with endogenous arginine vasopressin.
Yang YL; Shen ZL; Zou Q; Tang Y; Huang T
Life Sci; 2009 Oct; 85(15-16):586-91. PubMed ID: 19723529
[TBL] [Abstract][Full Text] [Related]
16. Effects of physostigmine on the startle in guinea pigs: two mechanisms involved.
Philippens IH; Olivier B; Melchers BP
Pharmacol Biochem Behav; 1997 Dec; 58(4):909-13. PubMed ID: 9408195
[TBL] [Abstract][Full Text] [Related]
17. Acetylcholinesterase inhibition interacts with training to reverse spatial learning deficits after cortical impact injury.
Scremin OU; Norman KM; Roch M; Holschneider DP; Scremin AM
J Neurotrauma; 2012 Oct; 29(15):2457-64. PubMed ID: 22738336
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of human brain and RBC acetylcholinesterase (AChE) by heptylphysostigmine (HPTL).
Moriearty PL; Becker RE
Methods Find Exp Clin Pharmacol; 1992 Oct; 14(8):615-21. PubMed ID: 1494302
[TBL] [Abstract][Full Text] [Related]
19. Effects of subacute administration of physostigmine on blood acetylcholinesterase activity, motor performance, and soman intoxication.
Harris LW; Anderson DR; Lennox WJ; Solana RP
Toxicol Appl Pharmacol; 1989 Feb; 97(2):267-71. PubMed ID: 2922758
[TBL] [Abstract][Full Text] [Related]
20. Effect of cholinesterase inhibitor and exercise on choline acetyltransferase and acetylcholinesterase activities in rat brain regions.
Somani SM; Babu SR; Arneric SP; Dube SN
Pharmacol Biochem Behav; 1991 Jun; 39(2):337-43. PubMed ID: 1946575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
